Comparing the current results to its competitors, Mimedx Group Inc reported Revenue decrease in the 2 quarter 2026 year on year by -34.27 %, faster than the overall decrease of Mimedx Group Inc 's competitors by -7.64 %, recorded in the same quarter.
Mimedx Group Inc 's Comment on Competition and Industry Peers
The company utilizes a proprietary PURION process designed to preserve natural beneficial characteristics of tissue. Its allografts maintain biological properties and regulatory proteins, are safe, easy to use, storable at room temperature, and have a five-year shelf life. The skin substitutes market includes placental-tissue allografts, tissue-engineered living skin equivalents, xenografts derived from porcine, bovine, and fish skin, and collagen matrix products. Key publicly traded competitors in this market are Integra LifeSciences Holdings Corporation, Organogenesis, Inc., and Smith & Nephew plc. Additionally, numerous privately held companies compete regionally and nationally, particularly in physician office and associated care settings, with market dynamics influenced by Medicare reimbursement and pricing.
July 31, 2024
MIMEDX Announces Launch of HELIOGEN Fibrillar Collagen Matrix: A Revolutionary Step in Wound Healing and Surgical Procedures In a significant advancement for the medical community, MIMEDX, a pioneer in the development of regenerative medicine products, has announced the launch of its latest innovation, the HELIOGEN Fibrillar Collagen Matrix. This limited market release marks the company s first foray into the realm of xenografts, expanding its extensive portfolio of wound and surgical care solutions.The HELIOGEN product is designed to revolutionize how healthcare providers address complex wounds and surgical interventions. With a focus on enhancing healing processes, the Fibrillar Collagen Matrix offers uniq...
March 20, 2024
In a groundbreaking move, MIMEDX, a leading biopharmaceutical company specializing in advanced wound care solutions, has recently expanded its portfolio with the introduction of a revolutionary wound dressing. The strategic partnership has provided MIMEDX with exclusive rights to commercialize a 510(k) cleared, bovine-derived collagen matrix particulate, specifically designed for the management of exudating wounds. This breakthrough development marks a significant milestone in the field of wound care, addressing a critical need for more effective treatment options.Wealth Health: Advanced Wound Care Takes a Leap ForwardWound care is an extensive and well-established medical discipline, but the search for nove...
Anika Therapeutics Inc is a medical technology company that focuses on developing and commercializing therapeutic products to treat tissue-related disorders. Their business model revolves around conducting extensive research and development to create innovative therapies, partnering with healthcare professionals and distributors to bring their products to market, and generating revenue through the sale of these products worldwide. They also collaborate with other companies and academic institutions to enhance their product portfolio and expand their reach in the healthcare industry.
Establishment Labs Holdings Inc operates as a global aesthetic medical technology company. Their business model revolves around designing, developing, manufacturing, and marketing innovative medical devices and implants for improved aesthetic outcomes. Their products primarily focus on breast aesthetics and reconstruction, utilizing their proprietary Motiva Implants and Divina 3D simulation technology.
Femasys Inc is a medical technology company that focuses on developing and commercializing innovative solutions for women's healthcare, specifically in the areas of reproductive and urinary health. Their business model involves designing and manufacturing medical devices, obtaining regulatory approvals, and partnering with healthcare providers and distributors to bring their products to market.
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Inmode Ltd is a medical technology company that specializes in developing and commercializing minimally invasive aesthetic and medical solutions. They primarily operate on a direct-to-consumer model, selling their devices to physicians, medical spas, and clinics. In addition to device sales, they generate recurring revenue through consumable product sales and service contracts for their devices.
Sources:
Mimedx Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mimedx Group Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
